Apogee Therapeutics Inc (APGE) reported a third-quarter loss of $1.11 per share for fiscal 2025, surpassing Wall Street's consensus estimate of $1.21. Revenue remained at $0.0 billion, aligning with analyst expectations.
The results reflect the company's ongoing efforts in the biotechnology sector, where it is advancing novel biologics aimed at treating various inflammatory and immunology conditions, including atopic dermatitis and asthma. Apogee, headquartered in Waltham, Massachusetts, employs 196 full-time staff and went public on July 14, 2023. Its lead program, APG777, is under development for atopic dermatitis, while other notable programs include APG990, APG333, and APG808.
Apogee will host an earnings conference call to discuss these results and provide further insights into its business performance. Investors are encouraged to review the complete earnings release and listen to management's commentary for a comprehensive understanding of the quarter's outcomes and future direction.
Looking ahead, Apogee is expected to report EPS of $-1.13 and revenue of $0 on August 9, 2026, followed by an EPS of $-1.09 and revenue of $0 on May 10, 2026.